Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.

Tunn UW, Canepa G, Kochanowsky A, Kienle E

Prostate cancer and prostatic diseases1 Sept 2012Cited by 29 (Europe PMC)

PMID22733160DOI10.1038/pcan.2012.12PepBankPUB-22733160

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In prostate cancer patients, intermittent versus continuous leuprorelin showed no significant difference in time to androgen-independent progression up to 1000 days.
In plain wordsIn prostate cancer patients, intermittent and continuous leuprorelin showed no significant difference in time to androgen-independent progression up to 1000 days.
Peptide
Leuprolide
Outcome
No significant changeTime to androgen-independent progression
Study
n: not reported in source
Comparator
Continuous leuprorelin androgen deprivation
Outcome group
Tumor growth · Cancer
Studied dose
11.25 mg 3-month depotAs given in this study (human).
Source sentences
Summary
No significant difference was observed up to 1000 days between IAD and CAD with regard to time to androgen-independent progression.
3 context sentences(design, population, supporting numbers)
Summary · context
In this multicentre European prospective randomised phase III trial EC507, testosterone serum concentrations were analysed in prostate cancer patients with PSA progression after radical prostatectomy.
Summary · context
Patients were randomised to a continuous androgen deprivation (CAD) and IAD therapy using a 3-month depot with 11.25 mg leuprorelin acetate as microcapsule formulation.
Summary · context
A complete IAD cycle comprises both a 6-month androgen deprivation therapy plus the off-treatment time (OTT).
Report a problemFND-2273316005
02HumanNon-randomized trialEfficacy outcome
In prostate cancer patients receiving intermittent leuprorelin, testosterone returned to baseline in 79.3% during the first off-treatment cycle.
In plain wordsIn prostate cancer patients receiving intermittent leuprorelin, testosterone returned to baseline in 79.3% during the first treatment break.
Peptide
Leuprolide
Outcome
IncreaseTestosterone recovery in first off-treatment cycle
Study
n = 109
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg 3-month depot · 6-month androgen deprivation therapy per IAD cycleAs given in this study (human).
Measurements
Testosterone recovery to baseline, first IAD cycle
79.3%
IAD group, first off-treatment time
Source sentences
Summary
Testosterone recovery to baseline values was achieved in 79.3% during the first and in 64.9% during the second IAD cycle, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Serum testosterone recovery was recorded in 109 patients during OTT in the IAD group.
Summary · context
In this multicentre European prospective randomised phase III trial EC507, testosterone serum concentrations were analysed in prostate cancer patients with PSA progression after radical prostatectomy.
Summary · context
Patients were randomised to a continuous androgen deprivation (CAD) and IAD therapy using a 3-month depot with 11.25 mg leuprorelin acetate as microcapsule formulation.
Summary · context
A complete IAD cycle comprises both a 6-month androgen deprivation therapy plus the off-treatment time (OTT).
Report a problemFND-2273316001
03HumanNon-randomized trialEfficacy outcome
In prostate cancer patients receiving intermittent leuprorelin, median time to testosterone normalization was 100 days in the first cycle.
In plain wordsIn prostate cancer patients receiving intermittent leuprorelin, median time to normal testosterone was 100 days in the first cycle.
Peptide
Leuprolide
Outcome
Not applicableTime to testosterone normalization in first cycle
Study
n = 109
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg 3-month depot · 6-month androgen deprivation therapy per IAD cycleAs given in this study (human).
Measurements
Median time to testosterone normalisation, first cycle
100 days
IAD group, first cycle
Source sentences
Summary
Median time to testosterone normalisation was 100 days in the first and 115 days in the second cycle, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
Serum testosterone recovery was recorded in 109 patients during OTT in the IAD group.
Summary · context
In this multicentre European prospective randomised phase III trial EC507, testosterone serum concentrations were analysed in prostate cancer patients with PSA progression after radical prostatectomy.
Summary · context
Patients were randomised to a continuous androgen deprivation (CAD) and IAD therapy using a 3-month depot with 11.25 mg leuprorelin acetate as microcapsule formulation.
Summary · context
A complete IAD cycle comprises both a 6-month androgen deprivation therapy plus the off-treatment time (OTT).
Report a problemFND-2273316003
04HumanNon-randomized trialEfficacy outcome
In prostate cancer patients receiving intermittent leuprorelin, testosterone returned to baseline in 64.9% during the second off-treatment cycle.
In plain wordsIn prostate cancer patients receiving intermittent leuprorelin, testosterone returned to baseline in 64.9% during the second treatment break.
Peptide
Leuprolide
Outcome
IncreaseTestosterone recovery in second off-treatment cycle
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg 3-month depot · 6-month androgen deprivation therapy per IAD cycleAs given in this study (human).
Measurements
Testosterone recovery to baseline, second IAD cycle
64.9%
IAD group, second off-treatment time
Source sentences
Summary
Testosterone recovery to baseline values was achieved in 79.3% during the first and in 64.9% during the second IAD cycle, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
In this multicentre European prospective randomised phase III trial EC507, testosterone serum concentrations were analysed in prostate cancer patients with PSA progression after radical prostatectomy.
Summary · context
Patients were randomised to a continuous androgen deprivation (CAD) and IAD therapy using a 3-month depot with 11.25 mg leuprorelin acetate as microcapsule formulation.
Summary · context
A complete IAD cycle comprises both a 6-month androgen deprivation therapy plus the off-treatment time (OTT).
Report a problemFND-2273316002
05HumanNon-randomized trialEfficacy outcome
In prostate cancer patients receiving intermittent leuprorelin, median time to testosterone normalization was 115 days in the second cycle.
In plain wordsIn prostate cancer patients receiving intermittent leuprorelin, median time to normal testosterone was 115 days in the second cycle.
Peptide
Leuprolide
Outcome
Not applicableTime to testosterone normalization in second cycle
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg 3-month depot · 6-month androgen deprivation therapy per IAD cycleAs given in this study (human).
Measurements
Median time to testosterone normalisation, second cycle
115 days
IAD group, second cycle
Source sentences
Summary
Median time to testosterone normalisation was 100 days in the first and 115 days in the second cycle, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
In this multicentre European prospective randomised phase III trial EC507, testosterone serum concentrations were analysed in prostate cancer patients with PSA progression after radical prostatectomy.
Summary · context
Patients were randomised to a continuous androgen deprivation (CAD) and IAD therapy using a 3-month depot with 11.25 mg leuprorelin acetate as microcapsule formulation.
Summary · context
A complete IAD cycle comprises both a 6-month androgen deprivation therapy plus the off-treatment time (OTT).
Report a problemFND-2273316004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.